This could lead to situations where patients may also misattribute symptoms to their illicit GLP-1 medication, potentially missing the early diagnosis and treatment of unrelated illnesses, and as a result, poorer health outcomes for patients and increased costs to the NHS
As the GLP-1-based drug development landscape continues to unfold at dramatic pace, AMRA is at the forefront of designing effective biomarkers that elucidate insights beyond weight loss, supporting emerging therapies in demonstrating their safety and efficacy across a number of disease areas, including cardiovascular disease
External reviews evaluate the clinical merits of the denial against objective evidence, not the insurer's internal cost calculations, and they regularly overturn denials
This study characterized discontinuation and reinitiation of GLP-1 medications for a large population of patients with overweight or obesity who started a GLP-1 medication between 2018-2023
Befolkningsstatistik per r - Region Stockholm